Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

Wu, Kai; Choi, Angela; Koch, Matthew; Elbashir, Sayda M.; Ma, LingZhi; Lee, Diana; Woods, Angela; Henry, Carole; Palandjian, Charis; Hill, A V; Jani, Hardik; Quiñones, Julian; Nunna, Naveen; O’Connell, Sarah; McDermott, Adrian B.; Falcone, Samantha; Narayanan, Elisabeth; Colpitts, Tonya M.; Bennett, Hamilton; Corbett, Kizzmekia S.; Seder, Robert A.; Graham, Barney S.; Stewart‐Jones, Guillaume; Carfı́, Andrea; Edwards, Darin K.

doi:10.1016/j.vaccine.2021.11.001

Cited by 63 publications

(35 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the VOI and VOC variants designated prior to the emergence of the new variant Omicron (B.1.1.529), the B.1.351 variant showed the most significant impact on the efficacy of first-generation vaccines [ 40 , 43 , 46 ], and has been the main focus for the development of second-generation vaccines against SARS-CoV-2 variants [ 32 , 47 ]. In this study, the B.1.351 monovalent vaccine induced potent neutralizing activity against the B.1.351 variant, with an equivalent NAT 50 against the P.1 variant, which may be attributed to the fact that both B.1.351 and P.1 contain the K417N/T, E484K, and N501Y mutations [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

Wang

Sun

et al. 2022

Vaccines

View full text Add to dashboard Cite

With the emergence and rapid spread of new pandemic variants, especially variants of concern (VOCs), the development of next-generation vaccines with broad-spectrum neutralizing activities is of great importance. In this study, SCTV01C, a clinical stage bivalent vaccine based on trimeric spike extracellular domain (S-ECD) of SARS-CoV-2 variants Alpha (B.1.1.7) and Beta (B.1.351) with a squalene-based oil-in-water adjuvant was evaluated in comparison to its two corresponding (Alpha and Beta) monovalent vaccines in mouse immunogenicity studies. The two monovalent vaccines induced potent neutralizing antibody responses against the antigen-matched variants, but drastic reductions in neutralizing antibody titers against antigen-mismatched variants were observed. In comparison, the bivalent vaccine SCTV01C induced relatively higher and broad-spectrum cross-neutralizing activities against various SARS-CoV-2 variants, including the D614G variant, VOCs (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.1.529), variants of interest (VOIs) (C.37, B.1.621), variants under monitoring (VUMs) (B.1.526, B.1.617.1, B.1.429, C.36.3) and other variants (B.1.618, 20I/484Q). All three vaccines elicited potent Th1-biased T-cell immune responses. These results provide direct evidence that variant-based multivalent vaccines could play important roles in addressing the critical issue of reduced protective efficacy against the existing and emerging SARS-CoV-2 variants.

show abstract

Section: Discussionmentioning

confidence: 99%

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

Wang

Sun

et al. 2022

Vaccines

View full text Add to dashboard Cite

show abstract

“…Importantly, we saw no evidence that priming of the immune response with the original spike protein was detrimental when mice received a booster dose of ChAdOx1 expressing Beta (B.1.351) protein, consistent with preclinical and clinical data of other variant vaccines. 35 , 36 , 37 , 38 …”

Section: Discussionmentioning

confidence: 99%

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

et al. 2022

View full text Add to dashboard Cite

“…mRNA-1273.351 has advanced to Phase III clinical trials in the US to assess the immunological benefit of boosting with strain-specific spike proteins. 87 , 88 mRNA-1273 has now been approved for a third dose booster against SARS-CoV-2 in the US (NCT04927065). Pfizer and BioNTech have also evaluated the safety and immunogenicity of a third booster dose of the BNT162b2 vaccine.…”

Section: Rna Vaccines In Infectious Diseasesmentioning

confidence: 99%

The Development of mRNA Vaccines for Infectious Diseases: Recent Updates

Nitika¹,

Wei²,

Hui³

2021

IDR

View full text Add to dashboard Cite

mRNA-based technologies have been of interest for the past few years to be used for therapeutics. Several mRNA vaccines for various diseases have been in preclinical and clinical stages. With the outbreak of the COVID-19 pandemic, the emergence of mRNA vaccines has transformed modern science. Recently, two major mRNA vaccines have been developed and approved by global health authorities for administration on the general population for protection against SARS-CoV-2. They have been proven to be successful in conferring protection against the ongoing SARS-CoV-2 and its emerging variants. This will draw attention to various mRNA vaccines against infectious diseases that are in the early stages of clinical trials. mRNA vaccines offer several advantages ranging from rapid design, generation, manufacturing, and administration and have strong potential to be used against various diseases in the future. Here, we summarize the mRNA-based vaccines in development against various infectious diseases.

show abstract

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

Cited by 63 publications

References 46 publications

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

The Development of mRNA Vaccines for Infectious Diseases: Recent Updates

Contact Info

Product

Resources

About